10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
1 citations
,
April 2024 in “Journal of Autoimmunity” Interleukin-15 can help hair growth and protect hair follicles.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
July 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.
1 citations
,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
September 2025 in “Value in Health” May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
9 citations
,
January 2020 in “Skin appendage disorders” Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.
3 citations
,
September 2025 in “ChemMedChem” Multitarget drugs are needed to better treat complex diseases.
5 citations
,
December 2022 in “Genes” Genetic differences affect how people respond to COVID-19.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
2 citations
,
September 2025 in “Journal of Dermatological Treatment” Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
February 2026 in “International Journal of Molecular Sciences” Combining hyperthermia with natural compounds and conventional treatments improves cancer therapy effectiveness and reduces side effects.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
1 citations
,
May 2025 in “Journal of Cosmetic Dermatology” Blood metabolites significantly influence alopecia areata risk.
15 citations
,
December 2021 in “Pharmaceutics” The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.
14 citations
,
April 2021 in “International journal of molecular sciences” Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.
March 2024 in “Nutrients” Gynostemma pentaphyllum and its component damulin B could help hair grow by activating certain cell pathways.